Prostate Cancer International is
for 2011 by Great NonProfits
Three new articles in the June 15 issue of Oncology review the current data and the potential of proton beam radiation therapy (PBRT) as a first-line treatment for localized prostate cancer. The full texts of all three articles are available on line.
Filed under: Management, Treatment | Tagged: cost, lozalized, outcome, PBRT, proton beam, radiation therapy | 5 Comments »
Many prostate cancer patients and advocates will want to read yesterday’s article by New York Times correspondent Andrew Pollack entitled, “New drugs fight prostate cancer, but at high cost.” The article offers a commentary on recent advances in the treatment of advanced prostate cancer — and the economic consequences.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: advanced, cost, drugs | Comments Off
Paul Levy is the President and CEO of the Beth Israel Deaconess Medical Center in Boston (which is no small institution). He is not an enthusiastic advocate for the sudden growth in the number of proton beam radiation therapy (PBRT) centers in the US in the past 3 years. You want to see why, just [...]
Filed under: Management, Treatment | Tagged: cost, outcome, PBRT, proton, radiation therapy | Comments Off
Financial disincentives related to prescribing of LHRH agonists introduced in 2003 have clearly been associated with changes in actual physician prescriptions for drugs like Lupron and Zoladex in the immediately following years.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: appropriate use, cost, finance, incentive, LHRH agonist, Medicare | 3 Comments »
A common topic of discussion among some members of the patient and patient advocacy community is whether recommended management of prostate cancer for individual patients is driven by the potential revenue available to physicians and hospitals from differing recommendations.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, low risk, Management, revenue, Treatment | 7 Comments »
According to a media release from the American Cancer Society, a paper newly published online in Cancer suggests that some treatments for prostate cancer that are relatively low cost in the short term (i.e., in the first 12 months after treatment) may have higher costs over 5 years.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 1 year, 5 years, cost, Treatment | 6 Comments »
Another article in this week’s New England Journal of Medicine addresses the rapid increase in the number of robot-assisted surgical procedures carried out in the US between 2005 and 2008.
Filed under: Uncategorized | Tagged: cost, RALP, robot-assisted laparoscopic prostatectomy | 6 Comments »
Whether we like it or not, there are significant costs associated with the diagnosis and management of prostate cancer over time. And there are very few good data (to date) on the relative costs associated with differing types of treatment over time.
Filed under: Living with Prostate Cancer | Tagged: cost, Medicare | 2 Comments »
If you’ve recently noticed a 430+ percent increase in your bill for a single shot of leuprolide acetate (to more than $11,000), just click here for the explanation. Oh, sorry, no one can actually give you a coherent explanation (well, not if you got treated at a specific facility in Scottsdale, AZ).
Filed under: Living with Prostate Cancer, Treatment | Tagged: cost, drug, transparency | Comments Off
Two recent studies have examined the increasing economic burden of prostate cancer — in the USA and in selected European nations. The picture is not a pretty one.
Filed under: Diagnosis, Management, Treatment | Tagged: cost, Management | 3 Comments »
Many readers will be aware that robot-assisted laparoscopic prostatectomy (RALP) is more costly than either traditional laparoscopic surgery (LRP) or “open” radical retropubic prostatectomy (RRP). Now a group of researchers have actually documented some of the differences.
Filed under: Management | Tagged: cost, surgery | 1 Comment »
In today’s news reports we comment on: The possible link between obesity and prostate cancer risk The economic impact of widespread prostate cancer screening in Europe The potential roles of tumor volume and PSMs in projecting need for adjuvant radiotherapy post-surgery Biochemical progression after treatment with degarelix (at up to 1 year)
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: adiponectin, adjuvant radiation, biochemical failure, cost, Degarelix, obesity, positive surgical margin, risk, tumor volume | Leave a Comment »
We now know how much it cost the Province of Ontario, in Canada, on average, to manage prostate cancer cases between 1995 and 2002. However, it is doubtful that these data would necessarily be applicable to the same time period in the USA or other nations.
Filed under: Management | Tagged: Canada, cost | 2 Comments »
An analysis by Roehrborn et al. has come up with a mean, per-patient cost of just over $13,000 for managing the care of a newly diagnosed prostate cancer patient for the first year after his diagnosis in the USA, inclusive of actual treatment costs.
Filed under: Management, Treatment | Tagged: cost, first year, Treatment | Leave a Comment »
Looking through my assorted notes from the meeting this morning after getting home late last night, there are four other poster presentations that are worth commenting on very specifically, and then a general comment that I would add.
Filed under: Management, Treatment | Tagged: abiraterone, active surveillance, anxiety, cost, depression, MDV3100, radical prostatectomy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site